Patienten mit Multipler Sklerose (MS), die mit dem Medikament Rituximab behandelt wurden, verfügen über ein deutlich kleineres Rückfall-Risiko als Patienten, die eine Standardbehandlung erhalten.

Fredrik Piehl, Professor of Neurology at the Department of Clinical Neuroscience at Karolinska Institutet and researcher at ...

MS patients on B-cell depleting therapies are still protected against COVID-19 risk due to greater anti-viral T-cell activity ...

Zwischen 50 und 60 erreichen Menschen mit Multipler Sklerose ein Alter, in dem die Medikamente deutlich weniger wirken – ...

Rituximab is a human/mouse chimeric IgG1κ antibody ... effect profile in more than 50,000 transplant recipients. In MS patients, daclizumab is currently thought to take its therapeutic effect ...

For the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation announced the launch of the timsOmnitm system, a transformative new timsTOF-based mass spectrometer designed ...

This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

† Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, United States ‡ Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55905, ...

The following is a summary of “Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review,” published in the March 2025 issue of Advances in Rheumatology by ...

Early rituximab monotherapy led to a substantial delay in the need for new treatment in patients with advanced stage, asymptomatic, low tumour burden follicular lymphoma. After a median follow-up ...